ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The generic-drug maker Sandoz will spend $60 million on new production technology and increased capacity for making sterile penicillin active pharmaceutical ingredients (APIs) and sterile API mixtures in Palafolls, Spain. In a related action, Sandoz will close its site in Les Franqueses del Vallès, Spain, which produces oral APIs, in 2024. The moves complement the firm’s previously announced plan to spend $120 million to expand and modernize its amoxicillin plant in Kundl, Austria, which it calls the last of its kind in Europe.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X